Emergent Biosolutions (EBS) versus The Competition Head to Head Comparison
Emergent Biosolutions (NYSE: EBS) is one of 112 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Emergent Biosolutions to related businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.
Earnings and Valuation
This table compares Emergent Biosolutions and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Emergent Biosolutions||$512.21 million||$159.99 million||26.07|
|Emergent Biosolutions Competitors||$7.86 billion||$2.50 billion||0.98|
Emergent Biosolutions’ competitors have higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current ratings and price targets for Emergent Biosolutions and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Emergent Biosolutions Competitors||940||3772||5984||164||2.49|
Emergent Biosolutions presently has a consensus price target of $44.00, suggesting a potential upside of 15.61%. As a group, “Pharmaceuticals” companies have a potential upside of 26.02%. Given Emergent Biosolutions’ competitors higher probable upside, analysts plainly believe Emergent Biosolutions has less favorable growth aspects than its competitors.
Risk & Volatility
Emergent Biosolutions has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Emergent Biosolutions’ competitors have a beta of 0.86, indicating that their average stock price is 14% less volatile than the S&P 500.
This table compares Emergent Biosolutions and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Emergent Biosolutions Competitors||-3,615.35%||-50.25%||-8.94%|
Institutional and Insider Ownership
85.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 16.5% of Emergent Biosolutions shares are held by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Emergent Biosolutions beats its competitors on 9 of the 13 factors compared.
About Emergent Biosolutions
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.